
The potential ischemic benefits of novel oral antiplatelet therapy following an acute coronary syndrome (ACS) may be offset by a significant increase in major bleeding events, according to a meta-analysis recently published in the Archives of Internal Medicine. “We are already exposing these patients to several drugs that can produce…
Read more »
New-generation anticoagulant agents pose risks in treatment of acute coronary syndromes
The potential ischemic benefits of novel oral antiplatelet therapy following an acute coronary syndrome (ACS) may be offset by a significant increase in major bleeding events, according to a meta-analysis recently published in the Archives of Internal Medicine. “We are already exposing these patients to several drugs that can produce…
Read more »